Banco Santander SA Stock News

CNBC's Steve Liesman,and Stephen Stanley, chief US economist at Santander, joins 'The Exchange' to discuss dislocations in the market, the Fed's plan to drain excess liquidity, and the impact of bank

Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia

Les résultats de 2 études de phase III sur fitusiran publiées dans The Lancet et The Lancet Haematology montrent son potentiel à répondre aux besoins médicaux de tous les patients atteints d’h

As the first quarter of 2023 is coming to an end, now is an opportune time to assess the stock market performance of different countries. The U.S. stock market, as represented by the SPDR S&P 500 ETF

Spain's Santander on Friday said it was on track to meet its 2023 profitability targets despite the recent turmoil in the banking sector.

Availability of the Q1 2023 Memorandum for modelling purposes

Mise en ligne du document «Q1 2023 Memorandum for modelling purposes»

Santander US CEO Tim Wennes joins Yahoo Finance Live anchors Brad Smith and Julie Hyman to discuss the ongoing bank turmoil, preventing bank failures, regulation, consumer optimism, branch expansion,

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

U.S. stocks end modestly higher Friday, despite a jump in the cost of Deutsche Bank's credit-default swaps helping to reignite banking-sector worries.

U.S.-listed shares of European banks such as Deutsche Bank, UBS and Credit Suisse were under pressure, while

Coinbase, Chewy, Regeneron, Accenture and First Republic were some of the most active shares on Thursday.

Jurrien Timmer, director of global macro at Fidelity Investments, looked at the intersection of yield-curve inversions and the stock market.

Dupixent® pourrait devenir le premier médicament biologique contre la bronchopneumopathie chronique obstructive, après une étude pivot montrant une réduction significative des exacerbations

Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial